Structure Therapeutics In... (GPCR)
NASDAQ: GPCR
· Real-Time Price · USD
20.11
1.58 (8.53%)
At close: Aug 15, 2025, 3:59 PM
19.70
-2.04%
After-hours: Aug 15, 2025, 07:38 PM EDT
Structure Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 |
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | 1.33M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 853.99K | n/a | n/a | n/a | 231.74K | 658.93K | 280.92K | 351.02K | 160.26K | 153.7K | 147.75K | n/a | 154.23K | 152.21K | 131.25K |
Gross Profit | -853.99K | n/a | n/a | n/a | -231.74K | -658.93K | 1.05M | -351.02K | -160.26K | -153.7K | -147.75K | n/a | -154.23K | -152.21K | -131.25K |
Operating Income | -70.7M | -56.31M | -47.06M | -45.84M | -33.32M | -32.02M | -31.21M | -26.14M | -25.99M | -19.65M | -12.96M | -12.69M | -13.96M | -12.95M | -13.27K |
Interest Income | 8.96M | n/a | n/a | n/a | n/a | n/a | 6.22M | 2.69M | 2.79M | 1.7M | 899.51K | n/a | n/a | n/a | 1.91 |
Pretax Income | -61.74M | -46.73M | -36.34M | -33.88M | -25.98M | -26.01M | -24.99M | -23.46M | -23.16M | -17.95M | -12.05M | -12.34M | -13.88M | -13.02M | -13.28K |
Net Income | -61.88M | -46.83M | -36.48M | -33.98M | -26.03M | -26.04M | -24.67M | -23.86M | -23.28M | -17.98M | -11.88M | -13.93M | -13.95M | -13.08M | -15.43K |
Selling & General & Admin | 14.94M | 13.44M | 13.57M | 13.24M | 11.27M | 11.34M | 10.75M | 8.63M | 6.58M | 6.51M | 4.6M | 3.53M | 3.78M | 4.46M | 3.37K |
Research & Development | 54.9M | 42.87M | 33.49M | 32.6M | 22.05M | 20.68M | 20.18M | 17.52M | 19.41M | 13.13M | 8.36M | 9.16M | 10.18M | 8.49M | 9.91K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 69.84M | 56.31M | 47.06M | 45.84M | 33.32M | 32.02M | 30.93M | 26.14M | 25.99M | 19.65M | 12.96M | 12.69M | 13.96M | 12.95M | 13.27K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | 6.01M | 9.58M | 2.69M | 2.83M | n/a | n/a | n/a | n/a | 69K | 1K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | -205.62K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 70.7M | 56.31M | 47.06M | 45.84M | 33.32M | 32.02M | 31.21M | 26.14M | 25.99M | 19.65M | 12.96M | 12.69M | 13.96M | 12.95M | 13.27K |
Income Tax Expense | 139.49K | 98K | 136K | 92K | 53K | 29K | -314.14K | 405K | 118K | 25K | -180K | 73K | 64K | 60K | 81.00 |
Shares Outstanding (Basic) | 19.18M | 57.35M | 57.29M | 57.21M | 49.41M | 46.57M | 46.41M | 38.32M | 38.25M | 37.42M | 36.59M | 39.12M | 36.59M | 36.59M | 36.59M |
Shares Outstanding (Diluted) | 19.18M | 57.35M | 57.29M | 57.21M | 49.41M | 46.57M | 46.41M | 38.32M | 38.25M | 37.42M | 36.59M | 39.12M | 36.59M | 36.59M | 36.59M |
EPS (Basic) | -3.23 | -0.82 | -0.63 | -0.6 | -0.53 | -0.56 | -0.53 | -0.62 | -0.6 | -0.48 | -0.32 | -1.27 | -0.42 | -0.36 | -0.42 |
EPS (Diluted) | -3.23 | -0.82 | -0.63 | -0.6 | -0.53 | -0.56 | -0.53 | -0.62 | -0.6 | -0.48 | -0.32 | -1.27 | -0.42 | -0.36 | -0.42 |
EBITDA | -60.88M | -56.04M | -46.79M | -45.57M | -33.08M | -31.79M | -30.91M | -26.14M | -25.91M | -19.58M | -12.88M | -12.62M | -13.9M | -12.88M | -13.17M |
EBIT | -61.74M | -56.31M | -47.06M | -45.84M | -33.32M | -32.02M | -30.99M | -26.14M | -25.99M | -19.65M | -12.96M | -12.69M | -13.96M | -12.95M | -13.27M |
Depreciation & Amortization | 853.99K | 274K | 273K | 265K | 232K | 658.93K | 280.92K | 351.02K | 160.26K | 153.7K | 147.75K | 76K | 154.23K | 152.21K | 131.25K |